Duke University study reveals challenges of clinical trials results - Triad Business Journal

"Drug companies and researchers do not promptly report the results of trials that test new and experimental drugs in humans, according to findings from a Duke University report. Perhaps surprisingly, when tax dollars go to fund these tests, the results are even less likely to be promptly reported than when industry funds the clinical trial. This study is particularly important for the Triangle as some of the world's largest clinical research organizations such as Quintiles (NYSE: Q), INC Research Holdings (NASDAQ: INCR), Parexel (NASDAQ: PRXL) and PRA Health Sciences (NASDAQ: PRAH) are all based here or have major operations here collectively employing thousands of scientists, sales, support and administrative staff. Of more than 13,000 clinical trials listed at the federal registry ClinicalTrials.gov, only 13.4 percent of eligible trials reported findings within the required one-year window, according to the Duke research, which was published Thursday in The New England Journal of Medicine. For industry-sponsored trials, the rate was 17 percent. It was 5.7 percent for trials funded by academic or government sources other than the National Institutes of Health and 8.1 percent for NIH-funded trials ..."